COGNITE
5.10.2021 13:02:10 CEST | Business Wire | Press release
In the midst of the largest industrial revolution, Cognite , a leader in industrial digitalization, announced the release of The Definitive Guide To Industrial DataOps . A first for the industry, the book defines and explains the emerging discipline of Industrial DataOps in language crafted for both business and IT professionals, while addressing the urgency driven by accelerating, data-driven shifts that modern organizations now navigate. The insights and industry expertise captured in the book also offer organizations practical advice on successful Industrial DataOps adoption and scaling. A request for proposal (RFP) guide, and a self-assessment to evaluate organizational readiness and map out challenges, round out the actionable insights and tools covered in the book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005582/en/
Industrial DataOps is already becoming a driving force in industrial transformations, helping accelerate digital maturity, enabling data teams to deliver more digital products, and realizing more operational value at scale. In a 2020 survey of global companies, McKinsey found organizations that embedded DataOps could see the volume of new features increase by 50 percent because data automation enables quicker development iterations.
“Data trust comes from connecting the dots between desired outcomes and relevant use-case-oriented data products,” says Forrester VP, Principal Analyst Michele Goetz. “An Industrial DataOps platform brings context to data conditions and ensures business impacting data anomalies are caught early to mitigate costly issues. A DataOps platform also ensures data complies with data models and output standards to drive results from event-based intelligence inside processes.”
‘The Definitive Guide to Industrial DataOps’ was written to de-hype industrial digitalization and to help make sense of how Industrial DataOps allows organizations to manage complex data. The book’s structure reflects the journey that industrial companies will take as they evaluate, adopt, and scale Industrial DataOps across their organizations. The early chapters cover the urgency of Industrial DataOps and get readers to take stock of their industrial organizations’ digital maturity. The core chapters address the discipline itself, its key principles, and how to best extract value from data, while the final chapters define the way forward: scaling Industrial DataOps and putting it into practice.
“Industrial DataOps is a crucial and necessary tool to make digital transformation possible in asset-intensive industries,” says John Markus Lervik, CEO and co-founder of Cognite. “It illustrates how to connect data from the IT and OT source to the data consumer with contextual tips that will empower organizations of all sizes to use it, innovate off of it, and reshape operations for efficiency, profitability, and sustainability. It is the strongest driver of change that will propel the industry forward, and this book will help companies as they navigate their way and capture immediate value at scale.”
“To make the promise of Industrial DataOps a reality for enterprises, ´The Definitive Guide to Industrial DataOps´ serves as a critical manual to not only understand this novel software category, but as well how it accelerates innovation and reduces time-to-value at each stage of a digital operations transformation,” says Pascal Brosset, Industry X Production & Operations Lead at Accenture.
The full book is available for download for free: The Definitive Guide To Industrial DataOps
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion™, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter @CogniteData or LinkedIn: https://www.linkedin.com/company/cognitedata .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom